Advertisement

Neurochemical Journal

, Volume 12, Issue 4, pp 366–372 | Cite as

Blood-Serum Glutamate in Patients with Depressive Disorders as a Potential Peripheral Marker of the Prognosis of the Effectiveness of Therapy

  • I. S. LosenkovEmail author
  • A. S. Boiko
  • L. A. Levchuk
  • G. G. Simutkin
  • N. A. Bokhan
  • S. A. Ivanova
Clinical Neurochemistry
  • 10 Downloads

Abstract

Depressive disorder is considered as an important medico-social problem due to its severity, chronic nature, and high level of clinical polymorphism. The precise biological mechanism of this pathology is still unknown. The latest data confirms the role of the glutamatergic system in the pathogenesis of depression. Here, 79 patients with depressive disorders (50 diagnosed with a “single depressive episode” and 29 with “recurrent depressive disorder”) who were treated with selective serotonin reuptake inhibitors (SSRIs) and 27 healthy control donors underwent complex clinical and biochemical examinations. The depression severity at the baseline and on the 14th and 28th days of treatment, as well as during remission, was evaluated using the 17-item Hamilton Depression Rating Scale (HDRS-17). The therapy response was evaluated using the CGI-I scale. The blood serum glutamate concentration was measured at the baseline. The concentration of glutamate was significantly higher in the group of patients compared to the controls. No difference in this parameter was observed between groups of patients. A positive correlation between the severity of depression at the 28th day and the glutamate concentration was found in the groups of patients with recurrent depressive disorder. No association between glutamate concentration and the CGI-I scale score, as well as remission, was found. A high glutamate level in blood serum of patients with depressive disorders could be an indicator of glutamatergic system dysregulation. This value in the future may be used as a predictor of the effectiveness of SSRI treatment in patients with recurrent depressive disorder.

Keywords

depression single depressive episode recurrent depressive disorder glutamate selective serotonin reuptake inhibitors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Krasnov, V.N., Rasstroistva affektivnogo spektra (Disorders of Affective Spectrum), Moscow, 2011.Google Scholar
  2. 2.
    Smulevich, A.B. and Dubnitskaya, E.B., Zhurnal Nevrologii i psikhiatrii im. S.S. Korsakova, 2012, vol. 122, no. 11 (2), pp. 11–20.Google Scholar
  3. 3.
    Schastnyi, E.D., Simutkin, G.G., Lebedeva, E.V., Yakovleva, A.L., Losenkov, I.S., Levchuk, L.A., Sergienko, T.N., Muslimova, E.F., Repin, A.N., Nonka, T.G., and Ivanova, S.A., Sibirskii Vestnik psikhiatrii i narkologii, 2016, no. 4 (93), pp. 26–32.Google Scholar
  4. 4.
    Murray, C.J.L. and Lopez, A.D., Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020, Geneva: World Health Organization, 1996.Google Scholar
  5. 5.
    Smulevich, A.B., Depressii pri somaticheskikh i psikhicheskikh zabolevaniyakh (Depression during Somatic and Psychic Diseases), Moscow, 2007.Google Scholar
  6. 6.
    Wong, D.T., Perry, K.W., and Bymaster, F.P., Nat. Rev. Drug. Discov., 2005, vol. 4, no. 9, pp. 764–774.CrossRefGoogle Scholar
  7. 7.
    Belmaker, R.H. and Agam, A., The New England Journal of Medicine, 2008, vol. 358, pp. 55–68.CrossRefGoogle Scholar
  8. 8.
    Nemeroff, C.B. and Owens, M.J., Clinical Chemistry, 2009, vol. 55, no. 8, pp. 1578–1579.CrossRefGoogle Scholar
  9. 9.
    Grigor’yan, G.A., Dygalo, N.N., Gekht, A.B., Stepanichev, M.Yu., and Gulyaeva, N.V., Uspekhi Fiziologicheskikh nauk, 2014, vol. 45, no. 2, pp. 3–19.Google Scholar
  10. 10.
    Gulyaeva, N.V., Biokhimiya, 2017, vol. 82, no. 3, pp. 441–448.Google Scholar
  11. 11.
    Tiganov, A.S., Kopeiko, G.I., Brusov, O.S., and Klyushnik, T.P., Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova, 2012, vol. 112, no. 11, pp. 65–72.Google Scholar
  12. 12.
    Uzbekov, M.G. and Maksimova, N.M., Zhurnal Nevrologii i Psikhiatrii, 2015, vol. 1, no. 2, pp. 52–55.CrossRefGoogle Scholar
  13. 13.
    Ferrari F. and Villa, R.F., Mol. Neurobiol., 2017, vol. 54, no. 7, pp. 4847–4865.CrossRefGoogle Scholar
  14. 14.
    Levchuk, L.A., Vyalova, N.M., Ivanova, S.A., Simutkin, G.G., Lebedeva, E.V., and Bokhan, N.A., Bulletin of Experimental Biology and Medicine, 2015, vol. 158, no. 5, pp. 638–640.CrossRefGoogle Scholar
  15. 15.
    Loonen, A.J. and Ivanova, S.A., Front. Hum. Neurosci., 2016, vol. 10, p.571.CrossRefGoogle Scholar
  16. 16.
    Trullas, R. and Skolnick, P., Eur. J. Pharmacol., 1990, vol. 185, no. 1, pp. 1–10.CrossRefGoogle Scholar
  17. 17.
    Berman, R.M., Cappiello, A., Anand, A., Oren, D.A., Heninger, G.R., Charney, D.S., and Krystal, J.H., Biol. Psychiatry, 2000, vol. 47, no. 4, pp. 351–354.CrossRefGoogle Scholar
  18. 18.
    Zarate, C.A., Jr., Singh, J.B., Carlson, P.J., Brutsche, N.E., Ameli, R., Luckenbaugh, D.A., Charney, D.S., and Manji, H.K., Arch. Gen. Psychiatry, 2006, vol. 63, no. 8, pp. 856–864.CrossRefGoogle Scholar
  19. 19.
    Lener, M.S., Niciu, M.J., Ballard, E.D., Park, M., Park, L.T., Nugent, A.C., and Zarate, C.A., Jr., Biol. Psychiatry, 2016, vol. 81, no. 10, pp. 886–897.CrossRefGoogle Scholar
  20. 20.
    Tokita, K., Yamaji, T., and Hashimoto, K., Pharmacol. Biochem. Behav., 2012, vol. 100, no. 4, pp. 688–704.CrossRefGoogle Scholar
  21. 21.
    Niciu, M.J., Ionescu, D.F., Richards, E.M., and Zarate, C.A., J. Neural. Transm. (Vienna), 2014, vol. 121, no. 8, pp. 907–924.CrossRefGoogle Scholar
  22. 22.
    Arnone, D., Mumuni, A.N., Jauhar, S., Condon, B., and Cavanagh, J., Eur. Neuropsychopharmacol., 2015, vol. 25, no. 8, pp. 1109–1117.CrossRefGoogle Scholar
  23. 23.
    Sanacora, G., Treccani, G., and Popoli, M., Neuropharmacology, 2012, vol. 62, no. 1, pp. 63–77.CrossRefGoogle Scholar
  24. 24.
    Lee, P.H., Perlis, R.H., Jung, J.Y., Byrne, E.M., Rueckert, E., Siburian, R., Haddad, S., Mayerfeld, C.E., Heath, A.C., Pergadia, M.L., Madden, P.A.F., Boomsma, D.I., Penninx, B.W., Sklar, P., Martin, N.G., Wray, N.R., Purcell, S.M., and Smoller, J.W., Transl. Psychiatry, 2012, vol. 2, e184. doi 10.1038/tp.2012.95CrossRefGoogle Scholar
  25. 25.
    Chang, L.C., Jamain, S., Lin, C.W., Rujescu, D., Tseng, G.C., and Sibille, E., PLoS. One, 2014, vol. 9, no. 3, e90980. doi 10.1371/journal.pone.0090980CrossRefGoogle Scholar
  26. 26.
    Uzbekov, M.G., Gurovich, I.Ya., and Ivanova, S.A., Sotsial’naya i Klinicheskaya Psikhiatriya, 2016, vol. 26, no. 1, pp. 5–11.Google Scholar
  27. 27.
    Küçükibrahimoglu, E., Saygin, M.Z., Caliskan, M., Kaplan, O.K., Unsal, C., and Goren, M.Z., Eur. J. Clin. Pharmacol., 2009, vol. 65, no. 6, pp. 571–577.CrossRefGoogle Scholar
  28. 28.
    Mauri, M.C., Ferrara, A., Boscati, L., Bravin, S., Zamberlan, F., Alecci, M., and Invernizzi, G., Neuropsychobiology, 1998, vol. 37, no. 3, pp. 124–129.CrossRefGoogle Scholar
  29. 29.
    Mauri, M.C., Boscati, L., Volonteri, L.S., Scalvini, M.E., Steinhilber, C.P., Laini, V., and Zamberlan, F., Neuropsychobiology, 2001, vol. 44, no. 3, pp. 134–138.CrossRefGoogle Scholar
  30. 30.
    Altamura, C.A., Mauri, M.C., Ferrara, A., Moro, A.R., D’Andrea, G., and Zamberlan, F., Am. J. Psychiatry, 1993, vol. 150, no. 11, pp. 1731–1733.CrossRefGoogle Scholar
  31. 31.
    Cheng, S.Y., Zhao, Y.D., Li, J., Chen, X.Y., Wang, R.D., and Zeng, J.W., Psychoneuroendocrinology, 2014, vol. 47, pp. 126–135.CrossRefGoogle Scholar
  32. 32.
    Kim, J.S., Schmid-Burgk, W., Claus, D., and Kornhuber, H.H., Arch. Psychiatr. Nervenkr., 1982, vol. 232, no. 4, pp. 299–304.CrossRefGoogle Scholar
  33. 33.
    Kasatkina, L.A. and Borisova, T.A., Int. J. Biochem. Cell. Biol., 2013, vol. 45, no. 11, pp. 2585–2595.CrossRefGoogle Scholar
  34. 34.
    Zlotnik, A., Gurevich, B., Tkachov, S., Maoz, I., Shapira, Y., and Teichberg, V.I., Exp. Neurol., 2007, vol. 203, no. 1, pp. 213–220.CrossRefGoogle Scholar
  35. 35.
    Hediger, M.A., Am. J. Physiol., 1999, vol. 227, no. 4, pp. 487–492.Google Scholar
  36. 36.
    Benatti, C., Blom, J.M., Rigillo, G., Alboni, S., Zizzi, F., Torta, R., Brunello, N., and Tascedda, F., CNS Neurol. Disord. Drug Targets, 2016, vol. 15, no. 4, pp. 414–433.CrossRefGoogle Scholar
  37. 37.
    Baranyi, A., Amouzadeh-Ghadikolai, O., Lewinski, D.V., Breitenecker, R.J., Stojakovic, T., März, W., Robier, C., Rothenhäusler, H.B., Mangge, H., and Meinitzer, A., Sci. Rep., 2017, vol. 7. doi 10.1038/srep43642Google Scholar
  38. 38.
    Boiko, A.S., Losenkov, I.S., Levchuk, L.A., Simutkin, G.G., and Ivanova, S.A., Opera Medica et Physiologica, 2016, vol. 2, no. S1, pp. 33–34.Google Scholar
  39. 39.
    Steiner, J., Bogerts, B., Sarnyai, Z., Walter, M., Gos, T., Bernstein, H.G., and Myint, A.M., World J. Biol. Psychiatry, 2012, vol. 13, no. 7, pp. 482–492.CrossRefGoogle Scholar
  40. 40.
    Bobula, B., Tokarski, K., and Hess, G., Neuroscience, 2003, vol. 120, no. 3, pp. 765–769.CrossRefGoogle Scholar
  41. 41.
    Bonanno, G., Giambelli, R., Raiteri, L., Tiraboschi, E., Zappettini, S., Musazzi, L., Raiteri, M., Racagni, G., and Popoli, M., J. Neurosci., 2005, vol. 25, no. 13, pp. 3270–3279.CrossRefGoogle Scholar
  42. 42.
    Nowak, G., Pomierny-Chamiolo, L., Siwek, A., Niedzielska, E., Pomierny, B., Palucha-Poniewiera, A., and Pilc, A., Neuropharmacology, 2014, vol. 84, pp. 46–51.CrossRefGoogle Scholar
  43. 43.
    Geddes, S.D., Assadzada, S., Sokolovski, A., Bergeron, R., Haj-Dahmane, S., and Béïque, J.C., Neuropharmacology, 2015, vol. 95, pp. 130–143.CrossRefGoogle Scholar
  44. 44.
    Björkholm, C., Frånberg, O., Malmerfelt, A., Marcus, M.M., Konradsson-Geuken, Å., Schilström B., Jardemark, K., and Svensson, T.H., Int. J. Neuropsychopharmacol., 2014, vol. 18, no. 3, p. 1–12.Google Scholar
  45. 45.
    Nowak, G., Legutko, B., Skolnick, P., and Popik, P., Eur. J. Pharmacol., 1998, vol. 342, nos. 2–3, pp. 367–370.CrossRefGoogle Scholar
  46. 46.
    Wolak, M., Siwek, A., Szewczyk, B., Poleszak, E., Bystrowska, B., Moniczewski, A., Rutkowska, A., Mlyniec, K., and Nowak, G., Pharmacol. Rev., vol. 67, no. 3, pp. 490–493.Google Scholar
  47. 47.
    Coplan, J.D., Gopinath, S., Abdallah, C.G., and Berry, B.R., Front. Behav. Neurosci., 2014, vol. 8. doi 10.3389/fnbeh.2014.00189Google Scholar

Copyright information

© Pleiades Publishing, Ltd. 2018

Authors and Affiliations

  • I. S. Losenkov
    • 1
    • 4
    Email author
  • A. S. Boiko
    • 1
  • L. A. Levchuk
    • 1
  • G. G. Simutkin
    • 1
  • N. A. Bokhan
    • 1
    • 2
  • S. A. Ivanova
    • 1
    • 3
  1. 1.Mental Health Research Institute, Tomsk National Research Medical CenterRussian Academy of SciencesTomskRussia
  2. 2.National Research Tomsk State UniversityTomskRussia
  3. 3.National Research Tomsk Polytechnic UniversityTomskRussia
  4. 4.TomskRussia

Personalised recommendations